How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

28,354 results for

Topical Corticosteroid

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. A prospective, randomized clinical study comparing drug eluting stent therapy and intranasal corticoid steroid therapy in the treatment of patients with chronic rhinosinusitis. (Abstract)

A prospective, randomized clinical study comparing drug eluting stent therapy and intranasal corticoid steroid therapy in the treatment of patients with chronic rhinosinusitis. To conduct the first prospective, randomized controlled clinical trial comparing the efficacy of a drug-eluting stent (DES) (the Relieva StratusTM MicroFlow Spacer) and topical intranasal corticosteroid therapy in patients with chronic rhinosinusitis (CRS).Sixty-three adult patients with ethmoiditis were randomized (...) in the nasal spray group, but in the DES group a significant difference was noted only at three months. There was a statistically significant increase in total nasal cavity volumes in the corticosteroid spray group, but not in the DES group.We found that patients benefitted from DES and the corticosteroid nasal spray. We could not find any significant difference between the treatments, except the greater increase in the total nasal cavity volumes favouring the nasal spray group. Because of the very good

2017 Rhinology Controlled trial quality: uncertain

42. Analysis of Inhaled Corticoid Prescriptions in General Medicine

the rate of consultations where all the elements required for guiding the prescription of an inhaled corticoid are available. The secondary objectives are: Identify other factors associated with decision-making Identify the causes of inhaled corticosteroid stopping (de-prescription) Condition or disease Asthma Chronic Obstructive Pulmonary Disease Study Design Go to Layout table for study information Study Type : Observational Estimated Enrollment : 80 participants Observational Model: Case-Only Time (...) Perspective: Cross-Sectional Official Title: Analysis of Inhaled Corticoid Prescriptions in General Medicine Actual Study Start Date : July 13, 2017 Actual Primary Completion Date : July 1, 2018 Estimated Study Completion Date : December 31, 2018 Resource links provided by the National Library of Medicine related topics: Groups and Cohorts Go to Group/Cohort Study population Adults consulting with one of the participating general practitioners and requiring long term inhaled corticoids and monitoring

2017 Clinical Trials

43. Corticosteroid-eluting bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitis

via small openings (ostia). Rhinosinusitis occurs when the mucosal lining of the paranasal sinuses becomes inflamed and infected. Typical symptoms include fever, pain and tenderness over the infected area, together with a blocked or runny nose. Acute rhinosinusitis frequently resolves spontaneously with little or no treatment, but it can become chronic. 2.2 The symptoms of chronic rhinosinusitis are usually managed with analgesics, antibiotics, topical corticosteroids or nasal irrigation (...) . Foam dressings, nasal packing and middle meatal spacers are sometimes used after surgery to try to maintain sinus patency. 3 3 The procedure The procedure 3.1 Inserting a corticosteroid-eluting bioabsorbable stent or spacer for paranasal sinus disease aims to deliver topical corticosteroid after surgery and to maintain patency of the newly created drainage system. It is usually done with the patient under general anaesthesia, during functional endoscopic sinus surgery, which may include balloon

2016 National Institute for Health and Clinical Excellence - Interventional Procedures

44. A Randomized, Double-Blind, Placebo-Controlled Study of the Vasoconstrictor Potency of Topical 0.25% Desoximetasone Spray: A High to Super High Range of Potency (Class I to Class II) Corticosteroid Formulation. (Abstract)

A Randomized, Double-Blind, Placebo-Controlled Study of the Vasoconstrictor Potency of Topical 0.25% Desoximetasone Spray: A High to Super High Range of Potency (Class I to Class II) Corticosteroid Formulation. Topical corticosteroids offer great efficacy in controlling a wide variety of dermatoses. Traditional ointment vehicles are messy and difficult to apply, which might limit adherence. Alternative vehicle formulations such as topical sprays might improve adherence due to their ease (...) of application. The potency of desoximetasone spray is not fully characterized.To evaluate the relative vasoconstrictive potency of desoximetasone 0.25% topical spray formulation.This is a randomized, blinded, single-center study comparing the vasoconstrictive properties of desoximetasone 0.25% topical spray to placebo and seven other known potency topical corticosteroid formulations. The primary endpoint was the degree of vasoconstriction measured using a colorimeter device.Thirty-two healthy subjects met

2018 Journal of drugs in dermatology : JDD Controlled trial quality: predicted high

45. Topical Tacrolimus as Adjuvant Therapy to Corticosteroids in Acute Endothelial Graft Rejection After Penetrating Keratoplasty: A Randomized Controlled Trial: Erratum. (Abstract)

Topical Tacrolimus as Adjuvant Therapy to Corticosteroids in Acute Endothelial Graft Rejection After Penetrating Keratoplasty: A Randomized Controlled Trial: Erratum. 29985797 2018 09 10 1536-4798 37 10 2018 Oct Cornea Cornea Topical Tacrolimus as Adjuvant Therapy to Corticosteroids in Acute Endothelial Graft Rejection After Penetrating Keratoplasty: A Randomized Controlled Trial: Erratum. 1345 10.1097/ICO.0000000000001708 eng Journal Article United States Cornea 8216186 0277-3740 2018 7 10 6 0

2018 Cornea Controlled trial quality: predicted high

46. Topical Tacrolimus as Adjuvant Therapy to Corticosteroids in Acute Endothelial Graft Rejection After Penetrating Keratoplasty: A Randomized Controlled Trial. (Abstract)

Topical Tacrolimus as Adjuvant Therapy to Corticosteroids in Acute Endothelial Graft Rejection After Penetrating Keratoplasty: A Randomized Controlled Trial. To evaluate the efficacy of topical tacrolimus 0.05% as adjuvant therapy to corticosteroids in the treatment of acute endothelial rejection of a penetrating keratoplasty (PKP) graft.Patients with the clinical diagnosis of acute endothelial rejection of a PKP graft were randomized into 2 groups-group 1: receiving topical tacrolimus 0.05 (...) % as adjuvant therapy to corticosteroid treatment and group 2: receiving only corticosteroid treatment. Main outcome measures were rejection reversal, time to rejection reversal, and recurrence of rejection.Thirty-one eyes of 31 patients (17 and 14 eyes in group 1 and 2, respectively) were included in the study. The rejection episode completely resolved in 88.2% of patients in group 1 and 85.7% of patients in group 2 [hazard ratio = 0.60, 95% confidence interval (CI) = 0.28-1.29, P = 0.191]. After adjusting

2018 Cornea Controlled trial quality: predicted high

47. Comparison of the effectiveness of topical silicone gel and corticosteroid cream on the pfannenstiel scar prevention - a randomized controlled trial. Full Text available with Trip Pro

Comparison of the effectiveness of topical silicone gel and corticosteroid cream on the pfannenstiel scar prevention - a randomized controlled trial. To compare the effects of topical silicone gel and corticosteroid cream for preventing hypertrophic scar and keloid formation following Pfannenstiel incisions.Fifty patients operated for benign gynecological diseases through primary Pfannenstiel incision were included. The wounds were randomly allocated to the treatment and control arms (...) with the control group and in the height, vascularity, and pigmentation parameters as compared with the silicone group. No side effects were experienced by the patients with either treatment and patient satisfaction was higher in the methylprednisolone group.The use of topical methylprednisolone cream in fresh wounds at the postoperative early period appears to be promising.

2018 Ginekologia polska Controlled trial quality: uncertain

48. Comparing clinical effects of photodynamic therapy as a novel method with topical corticosteroid for treatment of Oral Lichen Planus. (Abstract)

Comparing clinical effects of photodynamic therapy as a novel method with topical corticosteroid for treatment of Oral Lichen Planus. Oral lichen planus is an autoimmune disorder with several challenges in treatment. Photodynamic therapy has been proposed as a new treatment option for the disease.The present study compared the clinical effects of photodynamic therapy to dexamethasone mouthwash in the treatment of oral lichen planus lesions.In this randomized clinical trial, 30 patients

2018 Photodiagnosis and Photodynamic Therapy Controlled trial quality: uncertain

49. Vasoconstrictor potency of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam versus other topical corticosteroids used to treat psoriasis vulgaris. Full Text available with Trip Pro

Vasoconstrictor potency of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam versus other topical corticosteroids used to treat psoriasis vulgaris. It is important to determine the vasoconstrictor potencies of topical corticosteroids used to treat psoriasis to ensure appropriate clinical use.To compare the vasoconstrictive potencies of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) (Cal/BD) cutaneous (...) foam with other topical corticosteroids.In this Phase I, single-center, healthy volunteer study, Cal/BD foam, clobetasol propionate 0.05% cream (CP; very potent), BD 0.05% ointment (potent), mometasone furoate 0.1% cream (MF; potent), hydrocortisone-17-butyrate 0.1% ointment (HB; moderately potent), and foam vehicle were applied, then removed after 16 h. Skin blanching was visually assessed 2 h later (scale of 0-4).Thirty-six volunteers were randomized. Skin blanching with Cal/BD foam (median

2018 Journal of Dermatological Treatment Controlled trial quality: uncertain

50. A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis

A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have (...) reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis (BREEZE-AD7) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider

2018 Clinical Trials

51. Enhancement of the Effectiveness of Extracorporeal Shock Wave Therapy with Topical Corticosteroid in Treatment of Chronic Plantar Fasciitis: A Randomized Control Clinical Trial Full Text available with Trip Pro

Enhancement of the Effectiveness of Extracorporeal Shock Wave Therapy with Topical Corticosteroid in Treatment of Chronic Plantar Fasciitis: A Randomized Control Clinical Trial Chronic recalcitrant plantar fasciitis is a disabling condition. We presumed if shock wave could increase the permeability of skin and facilitate penetration of topical corticosteroid through the skin; the combinational therapeutic effect would be stronger than using shock wave alone. The study purpose was to utilize (...) the synergistic effect of shock wave and topical corticosteroid in treatment of plantar fasciitis.Patients in both groups (n = 40) received four sessions of shock wave with the same protocol at weekly intervals. At 30 min before each session, we used an occlusive dressing of topical clobetasol for the intervention group and Vaseline oil for the control group. Pain severity was assessed with visual analog scale (VAS) and modified Roles and Maudsley score (RMS) at baseline and 1 month and 3 months after

2018 Advanced biomedical research Controlled trial quality: uncertain

52. Treatment of penile lichen sclerosus with topical corticosteroids for over 25 years’ duration: A case report Full Text available with Trip Pro

Treatment of penile lichen sclerosus with topical corticosteroids for over 25 years’ duration: A case report Topical corticosteroids are currently recommended only for short-term management of flares of lichen sclerosus, with efficacy in halting disease progression. Given the chronic nature of this condition, there is a lack of literature surrounding the chronic effects of topical corticosteroids on the male genitalia with many dermatologists avoiding prescribing long term. This case report (...) aims to provide anecdotal observation for the long-term use of topical corticosteroids and details the long-term follow-up of an individual who used potent and superpotent topical corticosteroids for over 25 years without significant demonstrable side effects. A short review on relevant literature is provided.

2018 SAGE Open Medical Case Reports

53. Dupilumab in the management of topical corticosteroid withdrawal in atopic dermatitis: A retrospective case series Full Text available with Trip Pro

Dupilumab in the management of topical corticosteroid withdrawal in atopic dermatitis: A retrospective case series 30306110 2019 02 26 2352-5126 4 9 2018 Oct JAAD case reports JAAD Case Rep Dupilumab in the management of topical corticosteroid withdrawal in atopic dermatitis: A retrospective case series. 860-862 10.1016/j.jdcr.2018.06.012 Arnold Kathryn A KA University of Chicago Pritzker School of Medicine, Chicago, Illinois. Treister Alison D AD Northwestern University Feinberg School (...) of Medicine, Chicago, Illinois. Lio Peter A PA Department of Dermatology, Northwestern University, Chicago, Illinois. eng Case Reports 2018 10 03 United States JAAD Case Rep 101665210 2352-5126 BSA, body surface area IGA, Investigator's Global Assessment TCS, topical corticosteroid atopic dermatitis dupilumab topical corticosteroids topical steroid withdrawal 2018 10 12 6 0 2018 10 12 6 0 2018 10 12 6 1 epublish 30306110 10.1016/j.jdcr.2018.06.012 S2352-5126(18)30163-2 PMC6172441 Clin Exp Immunol. 2002

2018 JAAD Case Reports

54. Cushing Syndrome due to Inappropriate Corticosteroid Topical Treatment of Undiagnosed Scabies Full Text available with Trip Pro

Cushing Syndrome due to Inappropriate Corticosteroid Topical Treatment of Undiagnosed Scabies The uncontrolled sale of topical corticosteroids has become an important risk factor for the development of iatrogenic Cushing syndrome in children, especially in countries where medications are sold over the counter. This is exacerbated by the lack of information for both the patients and pharmacists. This report documents a series of eight cases of iatrogenic Cushing syndrome secondary (...) to an inappropriate use of topical steroids, due to a misdiagnosis of scabies.

2018 Tropical Medicine and Infectious Disease

55. Efficacy and Tolerability of a Medical Device Repairing Emollient Cream Associated with a Topical Corticosteroid in Adults with Atopic Dermatitis: An Open-label, Intra-individual Randomized Controlled Study Full Text available with Trip Pro

Efficacy and Tolerability of a Medical Device Repairing Emollient Cream Associated with a Topical Corticosteroid in Adults with Atopic Dermatitis: An Open-label, Intra-individual Randomized Controlled Study Medical device repairing emollient creams (MDRECs) are designed to repair and protect the skin barrier. In this study, we examined the added clinical benefit and tolerability of a MDREC when used in association with a moderately potent topical corticosteroid (TCS) for adults with atopic

2018 Dermatology and therapy Controlled trial quality: uncertain

56. Anti‐inflammatory potency testing of topical corticosteroids and calcineurin inhibitors in human volunteers sensitized to diphenylcyclopropenone Full Text available with Trip Pro

Anti‐inflammatory potency testing of topical corticosteroids and calcineurin inhibitors in human volunteers sensitized to diphenylcyclopropenone To quantify the anti-inflammatory potency of topical corticosteroids and topical calcineurin inhibitors by measuring the contact allergic response to a diphenylcyclopropenone (DPCP) challenge in de novo sensitized human volunteers.Two randomized, double-blind, vehicle-controlled studies were performed encompassing 76 volunteers: 29 in the first (...) of not only topical corticosteroids, but also of drugs that have no effect on vasoconstriction. The method allowed comparison of the potencies of four topical corticosteroids and two calcineurin inhibitors.© 2018 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.

2018 British journal of clinical pharmacology Controlled trial quality: uncertain

57. Topical Corticosteroid-Resolved Rubeosis Iridis with Neovascular Glaucoma Caused by Noninfectious Granulomatous Uveitis Full Text available with Trip Pro

Topical Corticosteroid-Resolved Rubeosis Iridis with Neovascular Glaucoma Caused by Noninfectious Granulomatous Uveitis We report a case of topical corticosteroid treatment-resolved rubeosis iridis with neovascular glaucoma (NVG) caused by noninfectious granulomatous uveitis.A 61-year-old woman with left ocular pain and blurred vision was referred to our department. Visual acuity and intraocular pressure (IOP) were 20/60 and 37 mm Hg in the left eye, respectively. Inflammatory cells, hyphema (...) , and rubeosis iridis were observed. All laboratory tests, including multiplex polymerase chain reaction for infection using aqueous humor, were negative, and there was neither retinal occlusive vasculitis nor retinal ischemia in the fundus. Our diagnosis was noninfectious granulomatous anterior uveitis-associated NVG. Topical corticosteroid treatment and anti-glaucoma agents resolved inflammation, rubeosis iridis, and NVG. IOP had decreased to 13 mm Hg by 1 month of treatment, and no recurrence

2018 Case reports in ophthalmology

58. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). Full Text available with Trip Pro

Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). Interleukin (IL)-13 plays a key role in type 2 inflammation and is an emerging pathogenic mediator in atopic dermatitis (AD).We investigated the efficacy and safety of lebrikizumab, an IL-13 monoclonal antibody, as an add-on to topical corticosteroid (TCS

2018 Journal of American Academy of Dermatology Controlled trial quality: predicted high

59. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a critical appraisal. Full Text available with Trip Pro

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a critical appraisal. Blauvelt et al. aimed to compare the long-term efficacy and safety of dupilumab with medium-potency topical corticosteroids (TCS) vs. placebo with TCS in adults with moderate-to-severe atopic dermatitis (AD).This multicentre randomized, double-blinded, placebo-controlled trial was conducted in hospitals, clinics and academic institutions

2018 British Journal of Dermatology Controlled trial quality: predicted high

60. Fractional Carbon Dioxide Laser Resurfacing in Combination With Potent Topical Corticosteroids for Hypertrophic Burn Scars in the Pediatric Age Group: An Open Label Study. (Abstract)

Fractional Carbon Dioxide Laser Resurfacing in Combination With Potent Topical Corticosteroids for Hypertrophic Burn Scars in the Pediatric Age Group: An Open Label Study. Lasers and potent topical corticosteroids are used as therapeutic options in hypertrophic burn scars.To assess the therapeutic effect of fractional CO2 laser resurfacing in combination with potent topical corticosteroids on hypertrophic burn scars in pediatric age group.Ten children (5-12 years) with postburn hypertrophic (...) the effect of topical or local anesthesia. At the time of final assessment, there was mean reduction of 4.2 (range: 2.8-7) in VSS. Reduction of VSS by ≥4 points was observed in 8 of 10 cases, whereas PGA revealed excellent response in 6 of 10 cases. No significant adverse effects were reported by any patient.Fractional CO2 laser resurfacing in combination with potent topical steroids leads to significant therapeutic benefits in children with postburn hypertrophic scars.

2018 Dermatologic Surgery

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>